Palbociclib and Exemestane are Active in Pretreated Low-Grade Serous Ovarian Cancer

Abstract

We describe a case of a 55-year-old woman with a rare metastatic micropapillary low-grade serous ovarian cancer who had been heavily pretreated. A KRAS-mutation and c-MYC-amplification were detected, and we initiated a therapy with the CDK4/6- inhibitor Palbociclib in combination with the steroidal aromatase inhibitor exemestane. We postulated that the combination therapy leads to a blocking of the c-MYCamplification-activated cell cycle, proliferation, and inhibition of apoptosis, further enhanced by other oncogenes like mutated RAS. This therapy showed a good and lasting response representing a new opportunity for therapy in heavily pretreated metastatic micropapillary low-grade serous ovarian cancer.